A HIV Vaccine Proves Elusive Again As J&J Study Fails

Virus Continues To Evade Vaccine Developers

 
• By Andrew McConaghie

Another vaccine failure shows that HIV’s ability to “attack, hijack and evade” the human immune system is still outwitting researchers, but J&J will continue with Phase III study of a related vaccine.

Janssen Leiden Netherlands
The HIV vaccine candidate used the same Ad26 viral vector as in J&J's COVID-19 vaccine - but found HIV a far more difficult virus to protect against.

More from Anti-infective

More from Therapy Areas